Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lyra Therapeutics ( (LYRA) ) has issued an announcement.
On February 2, 2026, Lyra Therapeutics disclosed that it had received a Staff Determination Letter from Nasdaq stating that the exchange intends to delist the company’s common stock, citing Lyra’s status as a public shell after suspending development of its lead drug candidate and laying off nearly all staff, as well as its failure to meet the minimum $2.5 million stockholders’ equity requirement. Nasdaq previously granted Lyra an extension to regain compliance but concluded the company did not meet the terms and lacks current operations, and although Lyra has requested a hearing before a Nasdaq Hearings Panel to appeal the decision—which temporarily stays the suspension—there is no assurance its listing will be maintained, underscoring heightened risks for shareholders and uncertainty over the company’s future as a publicly traded entity.
The most recent analyst rating on (LYRA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.
Spark’s Take on LYRA Stock
According to Spark, TipRanks’ AI Analyst, LYRA is a Neutral.
The score is driven primarily by weak financial performance (minimal revenue, large losses, heavy cash burn, and negative equity) and bearish technicals (price well below key moving averages with negative MACD). A highly negative corporate event (program halt, near-total workforce reduction, leadership changes, and strategic-alternatives process) adds material risk, while valuation metrics offer limited support due to ongoing losses and no dividend.
To see Spark’s full report on LYRA stock, click here.
More about Lyra Therapeutics
Lyra Therapeutics, Inc. is a biopharmaceutical company that had been developing LYR-210 as its lead product candidate. Following a January 12, 2026 decision by its board to suspend development of LYR-210 and implement a drastic reduction in force that terminated nearly all employees and converted its CEO and CFO to consultants, the company is now effectively without an operating business and has been characterized by Nasdaq as a public shell.
Average Trading Volume: 88,363
Technical Sentiment Signal: Sell
Current Market Cap: $3.35M
Find detailed analytics on LYRA stock on TipRanks’ Stock Analysis page.